Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. The post Ayble Health Secures $16M for Virtual Digestive Health Clinic appeared first on MedCity News.

Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines. The post Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo appeared first on MedCity News.

CMS will expand its ACCESS model starting in spring 2027 to cover heart failure, COPD, substance use disorders and tobacco cessation. The outcomes-based payment model, which launched in July with 160 participating providers, will now make roughly three in four Medicare beneficiaries eligible for at least one track. The post CMS Broadens ACCESS Model to New Chronic Conditions appeared first on MedCity News.

The next evolution in ADHD therapy needs to focus not only on drug efficacy but also on how treatment aligns with the ever-busy and demanding lives of patients, families, and caregivers. The post Extending ADHD Coverage for the Entire Active Day appeared first on MedCity News.

The INVEST Digital Health conference, which will spotlight the consumer influence in healthcare, will include a discussion on wearables. It is scheduled for October 29 at Pegasus Park in Dallas. Register today! The post The Shifting Role of Wearables in Healthcare appeared first on MedCity News.

Trump’s $500 ACA refunds offer immediate financial relief to some enrollees, but healthcare experts question whether they address the broader affordability challenges facing Americans. The post Trump’s $500 ACA Refunds: ‘We Shouldn’t Confuse a Check With a Healthcare Affordability Strategy’ appeared first on MedCity News.

North Immunology is going public in a reverse merger with Aethlon Medical. With eczema as the lead indication, the inflammation and immunology biotech aims to show its bispecific antibody offers efficacy and tolerability advantages over Sanofi’s immune disorder juggernaut, Dupixent. The post North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug appeared first on MedCity News.

After a near-miss with her own breast cancer diagnosis, Ariel Ganz co-founded Arben Ventures, a precision health and longevity fund that has backed 83 early-stage startups in three years. The post How a Cancer Diagnosis Shaped This VC’s Precision Health Thesis appeared first on MedCity News.

Historically, warming and positioning have been addressed independently because, in many surgical procedures, they do not significantly interfere with one another. However, that’s not the case in most robotic-assisted surgeries. The post The Missing Link in Surgical Safety: Integrating Patient Warming and Positioning appeared first on MedCity News.

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective blood-brain barrier. The deal comes as Novartis weathers several pipeline setbacks, including trial failures for neuroscience drug candidates. The post Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M appeared first on MedCity News.

As Medicare Advantage denial rates climb, health systems are dropping plans and steering patients back to traditional Medicare. Pearl Health CEO Michael Kopko thinks the original Medicare Advantage bargain has broken down — and that the model may never have been as efficient as policymakers assumed. The post As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead appeared first on MedCity News.

Clinicians have a responsibility to understand the risks posed by AI chatbots and to inform teen patients, their parents and caregivers about them. The post AI Isn’t a Therapist, but Many Teens Are Treating It Like One appeared first on MedCity News.

Hospitals’ operating margins fell to 1.4% in July, down from 2.2% in May and June, according to new data from Kaufman Hall. The margin decrease was driven largely by a seasonal slowdown in elective surgeries and payer mix pressures. The post Hospital Margins Fell This Summer Amid Outpatient Slowdown, Data Shows appeared first on MedCity News.

The Series C funding round was from The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. The post Thatch Secures $108M, Reaches $1B Valuation appeared first on MedCity News.

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available drugs that hit two targets, but other big pharma companies are also developing trispecific antibodies. The post GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma appeared first on MedCity News.